Back to the Future? The Fallopian Tube, Precursor Escape and a Dualistic Model of High-Grade Serous Carcinogenesis
Abstract
1. The Past
2. The Paradigm Shift
3. Unanswered Questions
4. Serous Cancer Precursors in the Fallopian Tube
5. Early Serous Proliferations and “Precursor Escape”
6. De-Mystifying a Paradox
7. Unanswered Questions
8. Conclusions
Funding
Acknowledgments
Conflicts of Interest
References
- Cannistra, S.A. Cancer of the ovary. N. Engl. J. Med. 1993, 351, 2519–2529. [Google Scholar] [CrossRef] [PubMed]
- Scully, R.E.; Young, R.H.; Clement, P.B. Atlas of Tumor Pathology; Tumors of the Ovary, Maldeveloped Gonads, Fallopian Tube and Broad Ligament; American Registry of Pathology, AFIP: Bethesda, MD, USA, 1998; p. 51. [Google Scholar]
- Friedman, L.S.; Ostermeyer, E.A.; Szabo, C.I.; Dowd, P.; Lynch, E.D.; Rowell, S.E.; King, M.C. Confirmation of 1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat. Genet. 1994, 8, 399–404. [Google Scholar] [CrossRef] [PubMed]
- Bell, D.A.; Scully, R.E. Early de novo ovarian carcinoma. A study of fourteen cases. Cancer 1994, 73, 1859–1864. [Google Scholar] [CrossRef]
- Henderson, J.T.; Webber, E.M.; Sawaya, G.F. Screening for Ovarian Cancer: An Updated Evidence Review for the U.S. Preventive Services Task Force [Internet]; Agency for Healthcare Research and Quality (US): Rockville, MD, USA, 2018.
- Zweemer, R.P.; van Diest, P.J.; Verheijen, R.H.; Ryan, A.; Gille, J.J.; Sijmons, R.H.; Jacobs, I.J.; Menko, F.H.; Kenemans, P. Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations. Gynecol. Oncol. 2000, 76, 45–50. [Google Scholar] [CrossRef] [PubMed]
- Piek, J.M.; van Diest, P.J.; Zweemer, R.P.; Jansen, J.W.; Poort-Keesom, R.J.; Menko, F.H.; Gille, J.J.; Jongsma, A.P.; Pals, G.; Kenemans, P.; et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J. Pathol. 2001, 195, 451–456. [Google Scholar] [CrossRef] [PubMed]
- Colgan, T.J. Challenges in the early diagnosis and staging of Fallopian-tube carcinomas associated with BRCA mutations. Int. J. Gynecol. Pathol. 2003, 22, 109–120. [Google Scholar] [CrossRef] [PubMed]
- Medeiros, F.; Muto, M.G.; Lee, Y.; Elvin, J.A.; Callahan, M.J.; Feltmate, C.; Garber, J.E.; Cramer, D.W.; Crum, C.P. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am. J. Surg. Pathol. 2006, 30, 230–236. [Google Scholar] [CrossRef] [PubMed]
- Lee, Y.; Miron, A.; Drapkin, R.; Nucci, M.R.; Medeiros, F.; Saleemuddin, A.; Garber, J.; Birch, C.; Mou, H.; Gordon, R.W.; et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J. Pathol. 2007, 211, 26–35. [Google Scholar] [CrossRef] [PubMed]
- Jarboe, E.A.; Pizer, E.S.; Miron, A.; Monte, N.; Mutter, G.L.; Crum, C.P. Evidence for a latent precursor (p53 signature) that may precede serous endometrial intraepithelial carcinoma. Mod. Pathol. 2009, 22, 345–350. [Google Scholar] [CrossRef] [PubMed]
- Vang, R.; Visvanathan, K.; Gross, A.; Maambo, E.; Gupta, M.; Kuhn, E.; Li, R.F.; Ronnett, B.M.; Seidman, J.D.; Yemelyanova, A.; et al. Validation of an algorithm for the diagnosis of serous tubal intraepithelial carcinoma. Int. J. Gynecol. Pathol. 2012, 31, 243–253. [Google Scholar] [CrossRef] [PubMed]
- Callahan, M.J.; Crum, C.P.; Medeiros, F.; Kindelberger, D.W.; Elvin, J.A.; Garber, J.E.; Feltmate, C.M.; Berkowitz, R.S.; Muto, M.G. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J. Clin. Oncol. 2007, 25, 3985–3990. [Google Scholar] [CrossRef] [PubMed]
- Vang, R.; Shih, IeM.; Kurman, R.J. Fallopian tube precursors of ovarian low- and high-grade serous neoplasms. Histopathology 2013, 62, 44–58. [Google Scholar] [CrossRef] [PubMed]
- Kindelberger, D.W.; Lee, Y.; Miron, A.; Hirsch, M.S.; Feltmate, C.; Medeiros, F.; Callahan, M.J.; Garner, E.O.; Gordon, R.W.; Birch, C.; et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am. J. Surg. Pathol. 2007, 31, 161–169. [Google Scholar] [CrossRef] [PubMed]
- Singh, N.; Gilks, C.B.; Hirschowitz, L.; Kehoe, S.; McNeish, I.A.; Miller, D.; Naik, R.; Wilkinson, N.; McCluggage, W.G. Primary site assignment in tubo-ovarian high-grade serous carcinoma: Consensus statement on unifying practice worldwide. Gynecol. Oncol. 2016, 141, 195–198. [Google Scholar] [CrossRef] [PubMed]
- Kurman, R.J.; Shih, IeM. The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded. Am. J. Pathol. 2016, 186, 733–747. [Google Scholar] [CrossRef] [PubMed]
- Gockley, A.A.; Elias, K.M. Fallopian tube tumorigenesis and clinical implications for ovarian cancer risk-reduction. Cancer Treat. Rev. 2018, 69, 66–71. [Google Scholar] [CrossRef] [PubMed]
- Nebgen, D.R.; Hurteau, J.; Holman, L.L.; Bradford, A.; Munsell, M.F.; Soletsky, B.R.; Sun, C.C.; Chisholm, G.B.; Lu, K.H. Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: A pilot study in women with BRCA1/2 mutations. Gynecol. Oncol. 2018, 150, 79–84. [Google Scholar] [CrossRef] [PubMed]
- Chen, F.; Gaitskell, K.; Garcia, M.J.; Albukhari, A.; Tsaltas, J.; Ahmed, A.A. Serous tubal intraepithelial carcinomas associated with high-grade serous ovarian carcinomas: A systematic review. BJOG 2017, 124, 872–878. [Google Scholar] [CrossRef] [PubMed]
- Kim, J.; Coffey, D.M.; Ma, L.; Matzuk, M.M. The ovary is an alternative site of origin for high-grade serous ovarian cancer in mice. Endocrinology 2015, 156, 1975–1981. [Google Scholar] [CrossRef] [PubMed]
- Auersperg, N. Ovarian surface epithelium as a source of ovarian cancers: Unwarranted speculation or evidence-based hypothesis? Gynecol. Oncol. 2013, 130, 246–251. [Google Scholar] [CrossRef] [PubMed]
- Dubeau, L. The cell of origin of ovarian epithelial tumours. Lancet Oncol. 2008, 9, 1191–1197. [Google Scholar] [CrossRef]
- McDaniel, A.S.; Stall, J.N.; Hovelson, D.H.; Cani, A.K.; Liu, C.J.; Tomlins, S.A.; Cho, K.R. Next-generation sequencing of tubal intraepithelial carcinomas. JAMA Oncol 2015, 1, 1128–1132. [Google Scholar] [CrossRef] [PubMed]
- Meserve, E.E.; Strickland, K.C.; Miron, A.; Soong, T.R.; Campbell, F.; Howitt, B.E.; Crum, C.P. Evidence of a Monoclonal Origin for Bilateral Serous Tubal Intraepithelial Neoplasia. Int. J. Gynecol. Pathol. 2018. [Google Scholar] [CrossRef] [PubMed]
- Craig, E.; Clarke, R.; Rushton, G.; McCluggage, W.G. Serous Tubal Intraepithelial Carcinoma (STIC)-like Lesions Arising in Ovarian Serous Cystadenofibroma: Report of 2 Cases. Int. J. Gynecol. Pathol. 2015, 34, 535–540. [Google Scholar] [CrossRef] [PubMed]
- Folkins, A.K.; Jarboe, E.A.; Saleemuddin, A.; Lee, Y.; Callahan, M.J.; Drapkin, R.; Garber, J.E.; Muto, M.G.; Tworoger, S.; Crum, C.P. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol. Oncol. 2008, 109, 168–173. [Google Scholar] [CrossRef] [PubMed]
- Barakat, R.R.; Federici, M.G.; Saigo, P.E.; Robson, M.E.; Offit, K.; Boyd, J. Absence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotes. Cancer 2000, 89, 383–390. [Google Scholar] [CrossRef]
- Howitt, B.E.; Hanamornroongruang, S.; Lin, D.I.; Conner, J.E.; Schulte, S.; Horowitz, N.; Crum, C.P.; Meserve, E.E. Evidence for a dualistic model of high-grade serous carcinoma: BRCA mutation status, histology, and tubal intraepithelial carcinoma. Am. J. Surg. Pathol. 2015, 39, 287–293. [Google Scholar] [CrossRef] [PubMed]
- Kotsopoulos, J.; Gronwald, J.; Karlan, B.; Rosen, B.; Huzarski, T.; Moller, P.; Lynch, H.T.; Singer, C.F.; Senter, L.; Neuhausen, S.L.; et al. Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation. Gynecol. Oncol. 2018, 150, 85–91. [Google Scholar] [CrossRef] [PubMed]
- Brown, P.O.; Palmer, C. The preclinical natural history of serous ovarian cancer: Defining the target for early detection. PLoS Med. 2009, 6, e1000114. [Google Scholar] [CrossRef] [PubMed]
- Ducie, J.; Dao, F.; Considine, M.; Olvera, N.; Shaw, P.A.; Kurman, R.J.; Shih, I.M.; Soslow, R.A.; Cope, L.; Levine, D.A. Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma. Nat. Commun. 2017, 8, 990. [Google Scholar] [CrossRef] [PubMed]
- Pothuri, B.; Leitao, M.M.; Levine, D.A.; Viale, A.; Olshen, A.B.; Arroyo, C.; Bogomolniy, F.; Olvera, N.; Lin, O.; Soslow, R.A.; et al. Genetic analysis of the early natural history of epithelial ovarian carcinoma. PLoS ONE 2010, 5, e10358. [Google Scholar] [CrossRef] [PubMed]
- Hutson, R.; Ramsdale, J.; Wells, M. p53 protein expression in putative precursor lesions of epithelial ovarian cancer. Histopathology 1995, 27, 367–371. [Google Scholar] [CrossRef] [PubMed]
- Meserve, E.E.K.; Brouwer, J.; Crum, C.P. Serous tubal intraepithelial neoplasia: The concept and its application. Mod. Pathol. 2017, 30, 710–721. [Google Scholar] [CrossRef] [PubMed]
- Mehra, K.K.; Chang, M.C.; Folkins, A.K.; Raho, C.J.; Lima, J.F.; Yuan, L.; Mehrad, M.; Tworoger, S.S.; Crum, C.P.; Saleemuddin, A. The impact of tissue block sampling on the detection of p53 signatures in fallopian tubes from women with BRCA 1 or 2 mutations (BRCA+) and controls. Mod. Pathol. 2011, 24, 152–156. [Google Scholar] [CrossRef] [PubMed]
- Labidi-Galy, S.I.; Papp, E.; Hallberg, D.; Niknafs, N.; Adleff, V.; Noe, M.; Bhattacharya, R.; Novak, M.; Jones, S.; Phallen, J.; et al. High-grade serous ovarian carcinomas originate in the fallopian tube. Nat. Commun. 2017, 8, 1093. [Google Scholar] [CrossRef] [PubMed]
- Soong, T.R.; Howitt, B.E.; Miron, A.; Horowitz, N.S.; Campbell, F.; Feltmate, C.M.; Muto, M.G.; Berkowitz, R.S.; Nucci, M.R.; Xian, W.; et al. Evidence for lineage continuity between early serous proliferations (ESPs) in the Fallopian tube and disseminated high-grade serous carcinomas. J. Pathol. 2018, 246, 344–351. [Google Scholar] [CrossRef]
- Zakhour, M.; Danovitch, Y.; Lester, J.; Rimel, B.J.; Walsh, C.S.; Li, A.J.; Karlan, B.Y.; Cass, I. Occult and subsequent cancer incidence following risk-reducing surgery in BRCA mutation carriers. Gynecol. Oncol. 2016, 143, 231–235. [Google Scholar] [CrossRef] [PubMed]
- Visvanathan, K.; Shaw, P.; May, B.J.; Bahadirli-Talbott, A.; Kaushiva, A.; Risch, H.; Narod, S.; Wang, T.L.; Parkash, V.; Vang, R.; et al. Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A. Multicenter Study. Cancer Prev. Res. 2018, 11, 697–706. [Google Scholar] [CrossRef] [PubMed]
- Saleemuddin, A.; Folkins, A.K.; Garrett, L.; Garber, J.; Muto, M.G.; Crum, C.P.; Tworoger, S. Risk factors for a serous cancer precursor (“p53 signature”) in women with inherited BRCA mutations. Gynecol. Oncol. 2008, 111, 226–232. [Google Scholar] [CrossRef] [PubMed]
- Shih, L.C.; Li, W.S.; Tsai, S.C.; Ke, Y.M.; Hsu, S.T.; Huang, S.F.; Chou, M.M.; Lu, C.H. Primary serous tubal intraepithelial carcinoma with multiple lymph node metastases. Taiwan J. Obstet. Gynecol. 2016, 55, 609–612. [Google Scholar] [CrossRef] [PubMed]
- Conner, J.R.; Meserve, E.; Pizer, E.; Garber, J.; Roh, M.; Urban, N.; Drescher, C.; Quade, B.J.; Muto, M.; Howitt, B.E.; et al. Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations. Gynecol. Oncol. 2014, 132, 280–286. [Google Scholar] [CrossRef] [PubMed]
- Powell, C.B.; Swisher, E.M.; Cass, I.; McLennan, J.; Norquist, B.; Garcia, R.L.; Lester, J.; Karlan, B.Y.; Chen, L. Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo- oophorectomy. Gynecol. Oncol. 2013, 129, 364–371. [Google Scholar] [CrossRef] [PubMed]
- Anglesio, M.S.; Wang, Y.K.; Maassen, M.; Horlings, H.M.; Bashashati, A.; Senz, J.; Mackenzie, R.; Grewal, D.S.; Li-Chang, H.; Karnezis, A.N.; et al. Synchronous Endometrial and Ovarian Carcinomas: Evidence of Clonality. J. Natl. Cancer Inst. 2016, 108, djv428. [Google Scholar] [CrossRef] [PubMed]
- Huang, H.S.; Hsu, C.F.; Chu, S.C.; Chen, P.C.; Ding, D.C.; Chang, M.Y.; Chu, T.Y. Haemoglobin in pelvic fluid rescues Fallopian tube epithelial cells from reactive oxygen species stress and apoptosis. J. Pathol. 2016, 240, 484–494. [Google Scholar] [CrossRef] [PubMed]
- Lin, S.-F.; Gerry, E.; Shih, I.-M. Tubal origin of ovarian cancer–the double-edged sword of haemoglobin. J. Pathol. 2017, 242, 3–6. [Google Scholar] [CrossRef] [PubMed]
- Crum, C.P.; Herfs, M.; Ning, G.; Bijron, J.G.; Howitt, B.E.; Jimenez, C.A.; Hanamornroongruang, S.; McKeon, F.D.; Xian, W. Through the glass darkly: Intraepithelial neoplasia, top-down differentiation, and the road to ovarian cancer. J. Pathol. 2013, 231, 402–412. [Google Scholar] [CrossRef] [PubMed]
1 | Fix the fallopian tubes for 2 h. |
2 | Amputate the distal third and thinly (1 mm intervals) section in a sagittal plane (longitudinally) to gain the maximum exposure of the mucosa to histologic review. |
3 | Section the remainder of the tube at 1 mm intervals. |
4 | Submit the entire tube for histologic review if the patient is suspected to be at higher risk for high-grade serous carcinomas (HGSC) or if the patient has a concurrent HGSC, other uterine or extra-uterine Mullerian epithelial malignancy. |
5 | In routine surgical cases, submit the distal fallopian tube as appropriate. |
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Soong, T.R.; Kolin, D.L.; Teschan, N.J.; Crum, C.P. Back to the Future? The Fallopian Tube, Precursor Escape and a Dualistic Model of High-Grade Serous Carcinogenesis. Cancers 2018, 10, 468. https://doi.org/10.3390/cancers10120468
Soong TR, Kolin DL, Teschan NJ, Crum CP. Back to the Future? The Fallopian Tube, Precursor Escape and a Dualistic Model of High-Grade Serous Carcinogenesis. Cancers. 2018; 10(12):468. https://doi.org/10.3390/cancers10120468
Chicago/Turabian StyleSoong, T. Rinda, David L. Kolin, Nathan J. Teschan, and Christopher P. Crum. 2018. "Back to the Future? The Fallopian Tube, Precursor Escape and a Dualistic Model of High-Grade Serous Carcinogenesis" Cancers 10, no. 12: 468. https://doi.org/10.3390/cancers10120468
APA StyleSoong, T. R., Kolin, D. L., Teschan, N. J., & Crum, C. P. (2018). Back to the Future? The Fallopian Tube, Precursor Escape and a Dualistic Model of High-Grade Serous Carcinogenesis. Cancers, 10(12), 468. https://doi.org/10.3390/cancers10120468